Verona Pharma PLC Holding(s) in Company (8343F)
August 01 2016 - 6:40AM
UK Regulatory
TIDMVRP
RNS Number : 8343F
Verona Pharma PLC
01 August 2016
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
1. Identity of the issuer or the underlying
issuer of existing shares to which voting
rights are attached: ii Verona Pharma
PLC
--------------------------------------------------- -----------------------------------------------------------------
2 Reason for the notification (please tick the appropriate box or boxes):
----------------------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights X
-------------------------------------------------------------------------------------------------- ------------------
An acquisition or disposal of qualifying financial instruments
which may result in the acquisition of shares already issued to
which voting rights are attached
-------------------------------------------------------------------------------------------------- ------------------
An acquisition or disposal of instruments with similar economic
effect to qualifying financial instruments
-------------------------------------------------------------------------------------------------- ------------------
An event changing the breakdown of voting rights
-------------------------------------------------------------------------------------------------- ------------------
Other (please specify):
-------------------------------------------------------------------------------------------------- ------------------
3. Full name of person(s) subject
to the notification obligation: iii OrbiMed Private Investments VI, LP
---------------------------------------- ----------------------------------------------------------------------------
4. Full name of shareholder(s)
(if different from 3.):iv
---------------------------------------- ----------------------------------------------------------------------------
5. Date of the transaction and date
on which the threshold is crossed July 29, 2016
or
reached: v
---------------------------------------- ----------------------------------------------------------------------------
6. Date on which issuer notified: July 28, 2016
---------------------------------------- ----------------------------------------------------------------------------
7. Threshold(s) that is/are crossed
or reached: vi, vii Greater than 5% ownership
---------------------------------------- ----------------------------------------------------------------------------
8. Notified details:
---------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares viii, ix
---------------------------------------------------------------------------------------------------------------------
Class/type of Situation previous Resulting situation after the triggering
shares to the triggering transaction
transaction
if possible using
the ISIN CODE
-------------------- ------------------------ ---------------------------------------------------------------------
Number of Number of Number of Number of voting % of voting rights
Shares Voting shares rights x
Rights
-------------------- ----------- ----------- --------------- -------------------------- ------------------------
Indire
Direct Direct xi ct xii Direct Indirect
-------------------- ----------- ----------- --------------- ---------------- -------- ----------- -----------
GB00B06GSH43 0 0 233,492,342 233,492,342 0 9.10% 0
-------------------- ----------- ----------- --------------- ---------------- -------- ----------- -----------
B: Qualifying Financial Instruments
--------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
--------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting % of voting rights
instrument date xiii Conversion Period rights that may
xiv be
acquired if the
instrument is
exercised/ converted.
------------------ ----------- ------------------- ----------------------- -------------------
C: Financial Instruments with similar economic effect to Qualifying Financial
Instruments
xv, xvi
------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
------------------------------------------------------------------------------------------------------
Type of financial Exercise Expiration Exercise/ Number of voting % of voting rights
instrument price date xvii Conversion rights instrument xix,
period xviii refers to xx
------------------ --------- ----------- -------------- ------------------- ---------------------
Nominal Delta
------------------ --------- ----------- -------------- ------------------- ----------- --------
Total (A+B+C)
------------------------------------------------------
Number of voting rights Percentage of voting rights
------------------------ ----------------------------
233,492,342 9.10%
------------------------ ----------------------------
9. Chain of controlled undertakings through which the voting rights and/or
the financial instruments are effectively held, if applicable: xxi
---------------------------------------------------------------------------------
These securities are held of record by OrbiMed Private Investments VI,
LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the sole general
partner of OPI VI, and OrbiMed Advisors LLC ("Advisors"), is the sole
managing member of GP VI. Samuel D. Isaly ("Isaly"), a natural person,
is the managing member of, and holder of a controlling interest in, Advisors.
---------------------------------------------------------------------------------
Proxy Voting:
--------------------------------------------------
10. Name of the proxy holder:
------------------------------------------------
11. Number of voting rights proxy holder will
cease to hold:
------------------------------------------------
12. Date on which proxy holder will cease to
hold voting rights:
------------------------------------------------
13. Additional information:
--------------------------------- --------------
14. Contact name: Douglas Coon
--------------------------------- --------------
15. Contact telephone number: 212-739-6400
--------------------------------- --------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUGUBGRUPQGUG
(END) Dow Jones Newswires
August 01, 2016 06:40 ET (10:40 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024
